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Purpose/Objective: To derive a reference, based on portal imaging 
acquisitions, to ensure the constance and stability of FFF beams using 
the parameters defined in Med. Phys. (39), 2012.  
Materials and Methods: On Varian TrueBeam linac, the PV-aS1000 
detector response was investigated for 6 and 10 MV FFF beams. With 
an adequate source to detector distance, e.g. SDD=150 cm, even with 
the maximum dose rate of 1400 and 2400 MU/min the integrated 
image does not present saturation. This allows its usage for dosimetric 
evaluations also for FFF beams. Feasibility tests were performed on 
four different TrueBeam machines (two equipped with a high-
definition MLC, HD-120MLC, and two with a standard Millenium 120-
MLC) for a predefined set of beam settings. Comparisons with 
calculations in the Eclipse treatment planning system with AAA 
(Anisotropic Analytical Algorithm) were also carried out. Different 
open square and rectangular fields were periodically acquired for 6 
and 10 MV FFF beams at SDD=150 cm for the maximum available dose 
rate, as well as at SDD=100 cm using a lower dose rate (800 MU/min), 
over a period of six months. Integrated images were converted into 
absorbed dose to water through the GLAaS algorithm [Med Phys (33), 
2006], adapted to FFF beams. Data were analysed and different 
parameters were recorded: dose on the beam central axis, profile 
parameters as unflatness,slope, peak position and symmetry. Similar 
analysis was also derived from measurements acquired with 2-D ion 
chamber array, StarCheck (PTW), and used as benchmark. 
Results: Dose profile percentage differences within the 80% of the 
field size, between measurements and AAA calculations, resulted in -
0.5±0.8% and -0.8±0.7% for 6 and 10 MV FFF, respectively. Similar 
deviation values were recorded for unflatness, symmetry and peak 
position. Constancy of repeated periodic portal image acquisition 
converted into dose resulted in the following values: output factors 
variation -0.13±0.17%, dose difference in the field region (80% of the 
field size): 0.15±0.26%. The gamma evaluation was conducted with 
two sets of distance-to-agreement and dose difference criteria of 
2mm/2% and 1mm/2%. The corresponding percentage of point passing 
the gamma evaluation were 99.7±0.6% and 99.3±1.6%, respectively for 
the two criteria. 
Conclusions: The possibility to effectively use the Portal Vision for 
open field quality assurance of FFF beams was assured. Constancy and 
stability evaluated with the profile parameters were consistent with 
other measurements or calculations. This fact allows to set-up fast 
and safe linac quality assurance procedures also for FFF beams.  
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Purpose/Objective: The aim of this work is to investigate the 
predictive power of the Gamma passing rate (%GP) IMRT QA metric in 
order to evaluate whether the standard action levels used by most 
clinics are justified. Sensitivity and specificity analysis between %GP 
and different dose discrepancy between planned and perturbed DVH is 
performed. The perturbed DVH is calculated by using a dedicated 
software, 3DVH (Sun Nuclear Corporation), which is able to modify the 
dose distribution calculated by the Treatment Planning System (TPS) 
according to the dose discrepancies detected with pre-treatment 
measurements. Sensitivity was calculated to correctly identify the 
pre-treatment plans with high dose errors, varying the Gamma 
Index(GI) criteria and the preselected thresholds. Also specificity was 
calculated. 
Materials and Methods: 27 prostate cancer patients and 15 head and 
neck cancer patients, treated with IMRT-sliding window technique, 
were analyzed. Pre-treatment verifications were performed for all 
patients’ plans by acquiring plane dose distributions of each 
treatment field with the diode array MapCheck (Sun Nuclear 
Corporation). Measured and calculated dose distributions were 
compared using the global and local GI method, and %GP were 
generated using the following acceptance criteria: 1%/1mm, 2%/2 
mm, and 3%/3 mm. Planar measured dose distributions, together with 
patient's DICOM RT Plan, Structure and Dose files from TPS were 
loaded into the 3DVH software. Percentage dose differences between 
DVHs, obtained by TPS and by 3DVH were calculated. A value of %GP 
of 95% and the mean absolute DVH dose error 3% and 5% were used as 
thresholds to calculate sensitivity and specificity. 
Results: The results are reported in the Table 1. We found an 
excellent sensitivity (>0.93) for global and local methods with 
2%/2mm and a good sensitivity (>0.80) with 3%/3mm for local 
normalization. Instead we obtained a poor sensitivity (<0.4) with 
3%/3mm for global normalization. Our results confirmed that in 
general the local normalization method is more sensitive than global. 
Obtained 3%/3mm specificity was always higher than 2%/2mm 
criterion and,in particular, for the threshold of %GP> 95%with a 
2%/2mm criterion, the specificity value was very low (<0.2). So, in 
this case, even if the sensitivity is excellent, is not applicable in 
clinical routine because in our experience only 11% of plans pass this 
threshold. To have a higher value of specificity (>0.6) and good 
sensitivity (0.9) is necessary to use a threshold of %GP>90% for 
2%/2mm criterion. 
  
Conclusions: The low sensitivity of 3%/3mm global gamma method 
and 95% of %GP threshold show that the most common published 
acceptance criteria have disputable predictive power for pre-patient 
IMRT QA. The %GP, although it provides the quantity of errors, does 
not specify the magnitude of errors. Further investigations are 
strongly advised concerning the clinical relevance of GI analysis.  
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Purpose/Objective: To assess in-vivo the dose delivered to the target 
volume during volumetric modulated arc therapy (VMAT) in patients 
with anal or rectal cancer using thermoluminescent dosimeters (TLDs) 
whose anatomical position was evaluated using cone-beam computed 
tomography scans (CBCTs). 
Materials and Methods: A new procedure was used to perform in-vivo 
dosimetry using TLDs placed in rectal probes in high-dose regions. 
Using CBCT images and image fusion, TLDs were located respect to 
planned treatments, and expected dose estimated. We present the 
results of 10 patients treated with VMAT for ano-rectal cancer. Eclipse 
ver.10 was used for planning and patients were treated on a 2100C/D 
Varian linac equipped with on-board imaging. The prescribed dose to 
the gross tumor volume (GTV) was 1.8 Gy and 2 Gy for patients with 
anal (n=8) and rectal (n=2) cancer, respectively. The delivered dose to 
the elective clinical target volume for rectal cancer patients was 1.8 
Gy per fraction, using a simultaneous integrated boost technique. Five 
TLDs were fitted in a Rando phantom to evaluate TLDs readings 
contribution resulting from CBCT imaging. 
Results: TLDs reading in the Rando phantom, after irradiation with a 
standard pelvis CBCT protocol, resulted in 2 cGy dose contribution for 
all 5 TLDs, approximately 1% of the prescribed dose. These readings 
were neglected in the present analysis.  
A total of 52 measurements (43 and 9 for patients with anal and rectal 
cancer, respectively) were analyzed. Six TLDs were placed on the GTV 
located at anal verge in the perianal skin. Median planned and 
measured doses were 1.8 Gy (range, 1.09-2.02 Gy) and 1.81 Gy 
(range, 0.94-2.14 Gy), respectively. In percentage of the prescribed 
dose it corresponded to 100% (range, 60.6-106.7%) and 100.5% (range, 
52.2-112.2%) for planned and measured values, respectively. Overall, 
TLD doses measurements differed by a median dose of 0.035 Gy, 
ranging between -0.16 and 0.21 Gy (median difference in percentage 
of 1.9%, range –8.9%/+11.7%) in comparison to the planned doses. 
Differences ≤5% or ≥5% between calculated and estimated doses were 
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observed in 6 and 8 measurements (total of 26.9%), respectively, but 
only 2 measurement were over 10%. Four of the six measurements on 
the anal verge showed difference of 5% or more between the 
calculated and estimated dose.  
Conclusions: With high dose gradients in VMAT treatments it is 
essential to know the correct position of TLDs in order to properly 
analyze the results of in-vivo dosimetry. This new procedure seems 
dealing with this issue, allowing validating and monitoring doses 
delivered to patients.  
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Purpose/Objective: The clinical importance of the discrepancies 
detected in pre-treatment IMRT QA is often difficult to interpret. This 
seems to be possible by using a recent commercial software, 3DVH 
(SunNuclear, USA), that relies on field QA data to reconstruct a 3D 
dose distribution in the patient. A study is planned in our Institute to 
compare IMRT calculated dose distributions to the delivered ones 
reconstructed from QA results. In this work, we present the feasibility 
study dealing with the validation of the used software and methods.  
Materials and Methods: The validation study introduced deliberate 
errors in a sample of clinical plans to simulate delivery/calculation 
errors (modified plan). Then the error-free beams were used to 
generate virtual planar QA measures and input to SNC Patient 
software, which generates a PDP (Planned Dose Perturbation) file 
containing information about QA and calculated doses. The DICOM RT 
files together with the PDP file were loaded into the 3DVH software to 
reconstruct the error-free 3D patient doses by perturbing the modified 
plan. MU delivery errors of ±4% were simulated in the TPS. MLC errors 
were simulated by opening and closing leaves of one MLC bank by 1 
mm or 2 mm. The comparison between the 3DVH reconstructed dose 
and the original unmodified plan is performed in terms of the main 
DVH parameters of PTVs and OARs. Finally, the 3DVH software was 
applied to a sample of 10 head-and-neck (H&N, highly modulated due 
to simultaneous delivery of different doses to 3 PTVs) clinical plans 
and relative pre-tx QA performed with a diode array (Mapcheck2, 
SunNuclear, USA). The 3D γ-matching rates of the reconstructed plans 
are compared with the γ-passing rate of per-beam planar measures to 
detect possible correlations. 
Results: Fig. 1 shows the impact on the main DVH parameters of the 
simulated errors, as given by the 3DVH software. As expected, dose 
(MU) errors have a larger impact on PTVs than changes in MLC 
positions. In particular, a ± 4% change in MU is associated to a change 
in the PTVs mean dose of + 4.16 ± 0.01% and -3.84 ± 0.01%, 
respectively, suggesting a slight bias of 0.2%. Similar results have been 
obtained for OARs’ mean dose, while the impact of MLC error results 
more important than MU change. As for the capability of the 3DVH 
software to accurately reconstruct the original plan from the modified 
plan by using the virtual planar measures, all results give an almost 
perfect match of the 2 plans. Small differences are found only for 
very small volumes such as parotids. Finally, the application of 3DVH 
to our 10 H&N clinical sample has shown no significant correlation 
between the γ passing rates of single beam QA and the 3D matching 
rate of the reconstructed plan; better correlation is found with the 
minimum value of γ passing rates obtained in QA per-beam measures. 
 
  
Conclusions: Validation of 3DVH software against TPS has shown good 
results. Application to clinical plans using real QA data shows that the 
dosimetric discrepancies detected in individual field QA are not 
correlated to the γ of the reconstructed plan.  
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Purpose/Objective: The purpose of the study is to clinically validate 
the Gated dose delivery for mobile targets with VMAT using Electronic 
Portal Imaging Device (EPID). 
Materials and Methods: The advantage of Gated RapidArc (G-RA) 
technology is that it reduce the margin of Internal Target volume (ITV) 
which reduces the dose to OAR's adjacent to the mobile tumours. G-
RA was delivered using the Varian Real-Time Position Management 
(RPM) system which uses external retro reflective infrared markers to 
generate gate-open signals of different durations. To assure the 
proper dynamic dose delivery and MLC position of G-RA treatments, 
we selected five lung cases and RA plans were created in Varian 
Eclipse(v10) Treatment Planning System (TPS). Verification plans were 
generated using portal dosimetry and Portal Dose Prediction Algorithm 
(PDIP v10) is used to predict the portal dose at the isocenter. All plans 
were executed in Clinac-iX treatment machine and portal dose images 
were acquired using EPID, while Infrared reflecting box is periodically 
moved to provide gating signal for RPM system.To evaluate the 
accuracy of dose delivery, measurements were performed for 
different duty cycles (80%, 50% & 20%) and were compared with the 
portal doses of non-gated RA of the same plan. Earlier the non-Gated 
RA plans were compared with the TPS predicted portal dose. Area 
gamma and dose difference was analyzed in portal dosimetry 
workspace in Eclipse for the criteria 2mm Distance to Agreement 
(DTA) & 2% Dose Difference (DD) and 3mm & 3%.MLC Dynalog files 
were analyzed and expressed as root mean square (RMS) of the 
deviations of individual leaves during treatment delivery. 
Results: The accuracy of gated RapidArc dose delivery is compared 
against the non gated RapidArc delivery using electronic portal 
imaging device. The average area gamma less than 1 for duty cycles 
80%, 50%,& 20% were 99.84(±0.19), 99.5(±0.29), 87.52(±1.57) for 2mm 
DTA & 2% DD and 100.0(±0.0), 99.98(±0.05), 98.96(±0.87) for 3mm 
DTA & 3% DD respectively. Average of maximum error root mean 
square for all MLC positions were 0.074mm (±0.0059), 




Conclusions: Gated RapidArc delivery validated using EPID and results 
exhibits that there is good agreement between delivery of G-RA and 
non gated RapidArc. For fast, accurate and its highspatial resolution, 
EPID can be used as a verification tool for gated RA delivery. 
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Purpose/Objective: Radiochromic films are recognized to be suitable 
for patient specific QA in IMRT treatments verification because of high 
spatial resolution, near-tissue equivalence and weak energy 
dependence. Challenges in radiochromic films dosimetry using a 
multichannel flatbed scanner, are related to uncertainties due mainly 
to scanner non-uniformity and film thickness difference within films 
